# A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency

> **NCT00662675** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 40 (actual)

## Conditions studied

- Exocrine Pancreatic Insufficiency
- Steatorrhea
- Malabsorption Syndromes
- Cystic Fibrosis

## Interventions

- **DRUG:** Pancrease MT 10.5, or MT 21
- **DRUG:** Placebo for Pancrease MT 10.5 or MT 21

## Key facts

- **NCT ID:** NCT00662675
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00662675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00662675, "A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00662675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*